WELCOME TO WEST MIDLANDS PHARMACOKINETICS NETWORK
ABOUT
A Pharmacokinetics network for the Midlands
For over 10 years our group of like minded scientists based within Aston University in central Birmingham, have focused on the provision of pharmacokinetics research, both pre-clinical and clinical on a national and international level. Our research focuses on developing virtual patients, with which to study the pharmacokinetics of drugs during drug discovery and development.
​
We also work across clinical areas, applying population pharmacokinetics to the study and causes of variability in drug concentrations among individuals, through sparse (plasma) sampling and mathematical models to explain sources of variability and approaches to dose optimisation.
​
We are keen to work with colleagues within the Midlands, please get in touch to discuss opportunities for collaboration.
PHARMACOKINETICS WORKSHOP
We provide basic and advanced training in pharmacokinetics to individuals with an academic or clinical background. We can also delivery bespoke training in a range of pharmacokinetics topics.  For a current list of free and paid training workshops, please click below.
PK/PD ANALYSIS
We can conduct PK/PD in-vitro and in-vivo (rodent) studies to support data generation and analysis. We are supported by the necessary expertise and apparatus for biophase analysis (HPLC, Mass-Spec etc)
MODELLING
Our in-silico modeling suite is equipped with a range of computational pharmacokinetic modeling software to support both non-compartmental and compartmental modeling in addition to a suite of packages to develop a-priori mechanistic models and population pharmacokinetic models.
REPRESENTATIVE PUBLISHED WORK
CLOPIDOGREL PHARMACOKINETICS IN MALAYSIAN POPULATION GROUPS
August 26, 2018
Zakaria ZH, Fong AYY, Badhan RKS. Clopidogrel Pharmacokinetics in Malaysian
Population Groups: The Impact of Inter-Ethnic Variability. Pharmaceuticals
(Basel). 2018 Jul 26;11(3). pii: E74. doi: 10.3390/ph11030074. PubMed PMID:
30049953; PubMed Central PMCID: PMC6161187.
THE REPURPOSING OF IVERMECTIN FOR MALARIA: A PROSPECTIVE PHARMACOKINETICS-BASED VIRTUAL CLINICAL TRIALS ASSESSMENT OF DOSING REGIMEN OPTIONS
August 2018
Badhan R, Zakaria Z, Olafuyi O. The Repurposing of Ivermectin for Malaria: A
Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing
Regimen Options. J Pharm Sci. 2018 Aug;107(8):2236-2250. doi:
10.1016/j.xphs.2018.03.026. Epub 2018 Apr 5. PubMed PMID: 29626533.
THE IMPACT OF CYP2B6 POLYMORPHISMS ON THE INTERACTIONS OF EFAVIRENZ WITH LUMEFANTRINE: IMPLICATIONS FOR PAEDIATRIC ANTIMALARIAL THERAPY
July 2018
Zakaria Z, Badhan RKS. The impact of CYP2B6 polymorphisms on the interactions
of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy.
Eur J Pharm Sci. 2018 Jul 1;119:90-101. doi: 10.1016/j.ejps.2018.04.012. Epub
2018 Apr 7. PubMed PMID: 29635009.
FIXED-DOSE COMBINATION ORALLY DISINTEGRATING TABLETS TO TREAT CARDIOVASCULAR DISEASE: FORMULATION, IN VITRO CHARACTERIZATION AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO ASSESS BIOAVAILABILITY.
March 2017
Dennison TJ, Smith JC, Badhan RK, Mohammed AR. Fixed-dose combination orally
disintegrating tablets to treat cardiovascular disease: formulation, in vitro
characterization and physiologically based pharmacokinetic modeling to assess
bioavailability. Drug Des Devel Ther. 2017 Mar 16;11:811-826. doi:
10.2147/DDDT.S126035. eCollection 2017. PubMed PMID: 28352156; PubMed Central
PMCID: PMC5358997.
